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Abstract: Pharmacotherapies for schizophrenic and cocaine psychoses are complex but similar
because of similarities in their brain neurochemistry and behavioral outcomes. Their neurochemical neuronal mechanisms of action, as shown in preclinical and clinical studies, involve
primarily dopaminergic dysfunction and, secondarily, neuroadaptive effects that seem to involve
central serotonergic function. Behavioral outcomes of both disorders include hyperactivity and
antipsychotic medications can ameliorate psychotic symptoms. Patients with both disorders
often arrive at emergency departments and present ﬂoridly psychotic with a predominance of
positive symptoms, often prompting physicians to select a typical antipsychotic medication such
as haloperidol. While this has become conventional wisdom, we believe that to use an atypical
antipsychotic medication, such as risperidone, in the treatment of both psychoses is quite rational
for long-term management of both positive and negative symptoms. Also, controlled clinical
studies have shown that risperidone, an atypical antipsychotic medication, is successful in the
treatment of cocaine dependence and withdrawal (Smelson et al 1997, 2002; Grabowski et al
2000). Furthermore, the availability and effectiveness of long-acting risperidone in injectable
form opens new possibilities for the long-term management of both disorders. In this paper, we
present data which show that the use of risperidone is plausible for effective pharmacotherapy
of schizophrenic and cocaine psychoses.
Keywords: schizophrenia, cocaine psychosis, psychopharmacotherapy, typical antipsychotic,
atypical antipsychotic, risperidone
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The treatment of schizophrenic psychosis demands complex solutions encompassing
the multiplicity of variables associated with its onset, psychoneurobiology, course,
and prognosis. The same can be said of cocaine psychosis. The following are clinical observations that underscore the relationship between schizophrenic and cocaine
psychoses: (1) psychostimulants can produce psychotic syndromes in normal subjects;
(2) psychostimulants at doses which would not be psychotogenic in normal subjects,
exacerbate psychotic symptoms in a majority of schizophrenic patients; (3) stress
precipitates psychotic behavior (Yui et al 1999); and (4) psychostimulants have been
shown to produce positive psychotic symptoms in neuroleptic-naïve schizophrenic
patients (Hietala et al 1995).
Indeed, similarities between and co-morbidity of schizophrenic and cocaine
psychoses appear over and again in the clinical literature over the last two decades
(Brady et al 1991; Serper et al 1999; Harris and Batki 2000; Green et al 2004; Cubells
et al 2005; Mauri et al 2006). For example, Cubells and colleagues (2005) have
reported that cocaine induces a psychotic syndrome, which is transient, delusional
and hallucinatory and covaries with the severity of cocaine-induced psychotic paranoia. Serper and colleagues (1999) have shown that behavior in patients with cocaine
intoxication and then acute abstinence mimics the positive and negative symptoms
of schizophrenia. Clinical data show that about 50% of the patients who suffer from
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schizophrenia have also been substance abusers at some time
during their illness and that schizophrenic patients often feel
the need to alleviate psychosis by using reinforcing drugs
(cf. Buckley 1998). Moreover, cocaine-abusing patients
are more likely to be diagnosed with schizophrenia of the
paranoid subtype and to exhibit more negative symptoms in
the schizophrenic psychotic syndrome than do non-substance
abusing patients (Lysaker et al 1994). In addition, Green
and colleagues (1999) have provided additional data that
show that the atypical antipsychotic medication, clozapine,
is beneﬁcial for patients with comorbid substance use and
schizophrenia.
Particularly relevant to the relationship between
schizophrenic and cocaine-induced psychosis are biochemical
data which show that both disorders are remarkably similar
in their neurochemical neuronal mechanism of action. Preclinical and clinical studies show that both disorders involve
primary dopaminergic dysfunction and that secondary
neuroadaptive effects seem to involve central serotonergic
function. Furthermore, concomitant behavioral outcomes for
both disorders include hyperactivity (Broderick and Phelix
1997; Angelopoulos et al 2002; Carlsson and Carlsson
2006).
Solutions for these related psychoses must address as
many facets of these disorders as necessary, and at least
include psychopharmacotherapy and appropriate psychotherapies. In this paper, we address psychopharmacotherapy, particularly research relating to the neuroscience and
therapeutics of antipsychotic agents and their applications
in schizophrenia and cocaine psychosis and abuse. Further,
we highlight salient points of this research together with
mechanisms and hypotheses published by other researchers,
and present illustrative clinical cases.

Schizophrenia: an overview
Schizophrenia, a chronic and debilitating disorder that usually manifests in late adolescence and young adulthood, is
the prototypical psychosis, a term that refers to behavior, ie,
symptoms and signs, that breaks from consensual reality.
Schizophrenia impairs several areas of brain functioning,
but especially 1) cognition (form and content of thought,
attention and concentration, insight, and judgment), 2) perception, 3) emotions, and 4) behavior (Andreasen 1987). It
is a major medical problem by any measure, present in all
cultures, and has been described in writings going back to
the 12th century BC. With lifetime prevalence in the United
States ranging from 1% to 2%, schizophrenia accounts for
over 2.5% of all medical expenditures, or about 50 billion
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dollars a year. Patients with schizophrenia occupy about
50% of all mental hospital beds and comprise about 16%
of all psychiatric patients who receive treatment, two thirds
of whom need hospitalization. Yet only about half of all
schizophrenics receive treatment regardless of illness severity. Schizophrenia often has serious individual and social
consequences and its emotional cost to patients and loved
ones is immeasurable.
Although etiological factors underlying the disorder
have not yet been fully elucidated, we accept the understanding that predominantly biological factors, including
genetic predisposition, transact with adverse environmental,
social, and psychological factors to create, precipitate, and
perpetuate the disorder. Findings such as neuroimaging
evidence of mesocorticolimbic decreased prefrontal cortex
activity and the precipitating and perpetuating power of expressed emotions, stressful life events, and social downdrift
corroborate this view (Verhoeff et al 2000). Furthermore,
the well-known dopamine hypothesis of schizophrenia,
dopaminergic hyperfunction in mesolimbic areas of the
brain (Stahl 2000), is now supported by direct evidence from
single photon emission computed tomography (SPECT),
wherein the unchallenged release of dopamine is elevated
in schizophrenic patients compared with controls (AbiDargham et al 2000). Dopamine D2 receptor occupancy
is critical to dose and to differences between typical and
atypical antipsychotic medication (Naikar et al 2006).
Finally, this hyperdopaminergic function in schizophrenia
may be accompanied by decreased glutamate function
(Kegeles et al 2000).
Arvid Carlsson’s group in Sweden has been conducting
pioneering research in schizophrenia, developing antipsychotic
compounds called “dopamine stabilizers” (stabilizers), which
are capable of ameliorating schizophrenia symptoms without
producing side effects (Rung et al 2005; Nilsson et al 2006).
These dopamine stabilizers preferentially target extrasynaptic
receptors while leaving synaptic transmission and basic dopamine function intact. Ohara (2007) has reported a further addition to the dopamine hypothesis of schizophrenia by showing
that an n-3 fatty acid deﬁciency can lead to reduced dopamine
concentration, number of dopamine vesicles and dopamine
(D2) receptors at prefrontal presynaptic terminals.
Serotonin, a secondary neuroadaptive mechanism in
schizophrenia, (Angelopoulos et al 2002) balances dopamine
in mesolimbic and mesocorticolimbic structures in the brain.
This dopamine-serotonin balance provides the leading
hypothesis for the mechanism of action of atypical antipsychotic medications.
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Advanced paternal age has been demonstrated to be more
prevalent in the history of persons with schizophrenia than in
that of unaffected persons, which Malaspina and colleagues
(2002) suggest, owes to the possibility of de novo mutations in paternal germ cells. Age of onset is earlier for men
compared to women even though both sexes end up being
equally affected. Prenatal viral infections and exposure to
certain drugs such as diuretics (Sorensen et al 2003) have
also been implicated in the etiology of schizophrenia. The
ﬁnding that more people with the disorder are born in the
cold months (Smits et al 2004) suggests that viral infection,
which can affect fetal brain development, particularly during
the 2nd gestational trimester, may be another causative factor.
Unknown developmental factors which may cause schizophrenia in later years may be due to increased dopaminergic
tone as opposed to hyperdopaminergic function (Carlsson
and Carlsson 2006).
Historically, Bleuler (1911) referred to the schizophrenic
disorder in the plural, perhaps already glimpsing its heterogeneity and probable etiological multiplicity. While the uncertainties remain, today we speak of schizophrenia as a brain
disorder, and we understand it better as a psychotic syndrome
whose signs and symptoms we treat. Thus, its distinguishing
features are grouped into two categories: positive symptoms, an exaggeration of normal functioning, and negative
symptoms, a deﬁcit in normal functioning. Thinking that is
disordered both in form and content, conveyed by disordered
speech, and hallucinations that are primarily auditory count
among the positive symptoms. Andreasen (1982) listed the
following negative symptoms: Affective ﬂattening, alogia,
avolition, anhedonia, and attentional deﬁcits. Although
positive symptoms are often ﬂorid, dramatic, and demand
immediate attention, while negative symptoms are insidious and low key, both categories can seriously disrupt the
person’s life, markedly diminishing its quality. Negative
symptoms have always been more difﬁcult to treat, often
understood as intractable proof of social downdrift.

Pharmacology of antipsychotic
medications
Typical and atypical antipsychotic medications differ in
side effect proﬁle because they also differ signiﬁcantly in
mechanism and site of action of therapeutic effect. Regarding side effect proﬁle, one ought to bear in mind that the
medication must be effective for its intended purpose and that
its beneﬁts must outweigh its risks. Typical antipsychotics
such as haloperidol that readily resolve positive symptoms,
are seemingly ineffective in the treatment of negative
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symptoms of psychosis (Carpenter et al 1988). The advent
of the atypical antipsychotics brought the reversal of both
symptom categories within range (Meltzer 1992; Conley and
Mahmoud 2001). This effectiveness led to important adjustments in our understanding of the mechanisms of action of
both drug categories. Typicals control positive symptoms
through their action as dopamine antagonists presumably
through high occupancy of dopamine D2 receptors in the
nigrostriatum (Farde et al 1988; Mukherjee et al 2001), an
action that can also produce anhedonia (Blum et al 1989) and
extrapyramidal side effects (EPS). Typicals have little effect
on serotonergic mechanisms (Broderick and Piercey 1998;
Ichikawa et al 1998). Conversely, atypicals act primarily
but not exclusively, on serotonin2/dopamine2 receptors in
mesocorticolimbic neurons to reduce positive and negative
symptoms, with little risk of EPS, likely due to serotonergic
modulation of dopamine (Meltzer and Nash 1991). The
serotonergic function of atypical antipsychotic medications
may also account for their effect of improving anhedonia and
affective disorders, as Meltzer (1989) reported.
Pharmacological behavioral studies in animal models also
provide a means of demonstrating differences between typical and atypical antipsychotics. Typicals inhibit hyperactivity
and stereotypy induced by administration of dopaminergic
drugs. They also produce catalepsy in similar dose ranges.
Under similar circumstances, atypicals selectively inhibit
hyperactivity without inducing catalepsy (Weiner et al 2000;
Wadenberg et al 2001). In animal models, perospirone, a
model serotonin2/dopamine2 receptor antagonist, contrary
to typicals, showed preferential ability to induce Fos protein
expression in the mesolimbic nucleus accumbens versus
nigrostriatal dorsolateral terminal (Ishibashi et al 1999).

Schizophrenia: a clinical case
Anthony came to the psychiatrist’s ofﬁce referred by his
primary care physician. He came accompanied by his mother
and appeared inordinately passive and dependent on her,
which appeared incongruous for an 18-year-old male. The
mother told the story; he often nodded in agreement.
He had gone to an Army boot camp in Virginia, just
days after his 18th birthday, 8 months before the doctor
visit. A month before the visit, he called the mother from
the Port Authority Bus Terminal in Midtown Manhattan,
New York City, and asked her to come pick him up. They
lived an easy half-hour subway ride away, in Queens,
another New York City borough. He had been used to
traveling around the entire city and knew it “like the back
of his hand,” so the mother was alarmed when he claimed
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he did not know how to get home or what to do. To the
mother, Anthony sounded like a broken man and she was
“shocked and worried sick.” She found him sitting on an
overstuffed duffel bag looking lost, eyes gazing into nothingness. Expressionless, he stood up and remained halfway
between limp and stiff as she hugged him and cried. He
asked her not to cry, saying he was ﬁne. When asked why
he had returned, he said he could not talk about it because
he was under surveillance. He claimed his thoughts and
his every move were being monitored and that he was in
grave danger. He asserted that he needed to refrain from
speaking. He showed her, in a bizarrely secretive way,
what amounted to his discharge papers from a psychiatric
ward in a hospital close to the base, where he had been
kept as an inpatient for most of the previous month. He
whispered he was going to have a dishonorable discharge
from the Army. Later he told his mother he had punched an
ofﬁcer who forced him to do night duty in “a clear effort”
to get him killed. He “defended” himself to avoid getting
killed, prompted by voices he heard running a commentary
about him, saying he would be a wimp not to ﬁght. He was
urgently hospitalized. He told his mother of a conspiracy
against him involving the base and hospital personnel who
gave him drugs that made him sick.
Now in the psychiatrist’s ofﬁce, he was calm, without
suicidal, violent, or homicidal ideas, intent, or plans, but still
feared for his life. Anthony had no prior acute or chronic illnesses or hospitalizations. There was no history of trauma or
injury. He denied alcohol or drug abuse, but acknowledged,
as did his mother, that for the ﬁrst three months of the year
prior to going to boot camp, he had joined the “wrong crowd”
and used a “lot of weed.” He had no problems with the law.
He failed the ﬁrst marking period in school that year, something very uncharacteristic since he was used to being an A
student. With mother’s approval he had decided to join the
Army to get away.
Anthony was born to term in a Spanish-speaking South
American country. His parents separated soon thereafter
and his mother relocated to New York where another family
member had settled. Anthony developed without trouble, as
his mother struggled to establish herself, and married again
a couple of years later to a man who was kind to Anthony.
Anthony traveled to South America yearly to spend time with
his father who died soon before his trouble in school began.
His father was “an alcoholic” who had hospitalizations for
medical, surgical, and psychiatric problems as he got older.
The mother could recall no history of psychiatric disorders
in her side of the family.
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A physical exam and laboratory tests yielded no
pathological ﬁndings. Anthony did not use prescribed or
over-the-counter medicines. Alcohol blood level and urine
toxicology for all drugs of abuse were negative.

Understanding and treating Anthony
Anthony’s history is, in most respects, a clear case of schizophrenia. Some of his behavioral difﬁculties (eg, lack of
initiative, inability to plan) suggest diminished functioning of
the prefrontal cortex. He is alert, fully oriented, and has average intelligence and intact memory in all spheres. However,
his thinking, insight, judgment, emotions, perception, and
behavior are seriously impaired. Anthony used a “lot of
weed” for three months, about one year prior to the clear onset
of symptoms. Though no clear causative relationship has
been established – and none is suggested here – cannabis use
has been correlated with earlier age of onset of schizophrenia,
and has been suggested to play a role in its development
(Bersani et al 2002), the illness often coursing with negative
symptoms. Anthony’s treatment regimen consisted of atypical antipsychotic medication to address both his positive and
signiﬁcant negative symptoms and supportive psychotherapy
to stabilize him emotionally, and to help him adhere to the
treatment regimen, and attend to important matters such as
family life, ﬁnances, and obtaining and maintaining a job.
In most cases, the administration of atypical antipsychotics in proper doses, should be the centerpiece of the standard
for long term care of persons with schizophrenia, a rationale
applied to the case above. In fact, in a 50 week, open-label
trial, long-acting risperidone in injectable form was effective in ameliorating schizophrenic symptoms (Docherty
et al 2007). Also, the use of atypical antipsychotics has
been demonstrated to reinforce participation in long-term
psychosocial counseling, corresponding with greater efﬁcacy
of overall treatment and improved quality-of-life (Rosenheck
et al 1998). In spite of this, one ought not to discount the
potentially serious side effects of atypicals, with which one
must become familiar so as to choose the most adequate
among drugs of the class for each speciﬁc case. It is important
to note that risperidone acts like an atypical in lower doses
but more like a typical at the upper end of the prescribing
range (Williams 2001).

Cocaine psychosis: an overview
Among the substances of abuse, cocaine is second only
to alcohol in number of emergency room visits, hospital
admissions, and generation of social problems, including
family violence. The lure for its use is intense euphoria and
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increased sexual desire and performance, both transient. The
down side is intense post-cocaine dysphoria, and compulsion
for further use.
Cocaine intoxication often courses with anorexia,
insomnia, anxiety, motor hyperactivity, and “speeded”
thinking and speech. There is increased adrenergic tonus,
manifested by diaphoresis, dilated but reactive pupils, hyperreﬂexia, and tachycardia. Stereotypical movements of face,
mouth, and extremities and even grand mal seizures may be
present. Local damage inﬂicted by cocaine depends on the
route of administration and includes rhinitis, when snorted,
and bronchitis, when inhaled as free-base. The situation may
escalate to hypertensive crises, hyperpyrexia, stroke, myocardial infarction, situations that may require heroic emergency
room measures aimed at preventing death. Cocaine psychosis
is another consequence of cocaine abuse also commonly
seen, especially in emergency rooms (Satel and Edell 1991;
Mendoza et al 1992; Taylor and Staby 1992; Tueth 1993;
Schwarz et al 1998).
A person with the above presentation may not furnish a
reliable history. Thus, before laboratory conﬁrmation is at
hand, it is useful to bear in mind that cocaine- and amphetamine-induced psychoses may be clinically indistinguishable
and their differential diagnosis with schizophrenia, difﬁcult.
Cocaine use becomes a chronic pattern of a few days’ heavy
binge followed by a “crash.” The person is often anhedonic,
irritable, anxious, and has low-key mood. Since it is associated with heavy use, cocaine psychosis is considered an
episodic event.
Preclinical research has shown that cocaine acts in presynaptic nigrostriatal and mesolimbic dopamine pathways,
by both blocking transporter reuptake and enhancing release
mechanisms, thus increasing neurotransmission (de Wit and
Wise 1977; Church et al 1987; Ritz et al 1987; Bradberry and
Roth 1989; Hurd and Ungerstedt 1989; Kalivas and Duffy
1990; Broderick 1991a, 1991b, 1992a, 1992b; Broderick
et al 1993). It is thought that increased neurotransmission
in mesolimbic and mesocorticolimbic dopamine reward
pathways emanates from the ventral tegmental area (Roberts
and Koob 1982; Goeders and Smith 1983; Evenden and
Ryan 1988; Einhorn et al 1988; Kalivas 1993; Broderick
and Phelix 1997).
In addition to its established effects on dopamine levels,
cocaine has been demonstrated to stimulate increased serotonin release in the nucleus accumbens (Broderick et al 1993;
Bradberry et al 1993). In fact, serotonin has been implicated
in cocaine’s electrophysiological, transporter, behavioral,
and reinforcing effects (Cunningham and Lakoski, 1988;
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Broderick 1991b, 1992a, 1992b, 2002; Carroll et al 1993;
Hall et al 2002). Mesolimbic and nigrostriatal serotonin
release increased rhythmic movement during animal natural
exploration whereas cocaine disrupted this rhythmic balance
(Broderick 2002).
We have focused on serotonin-dopamine interactions to
explain cocaine’s neurochemical and behavioral properties.
The literature shows that cocaine increases dopamine probably through serotonin 2C receptor action that is postsynaptically mediated. Also, adjunct mechanisms, such as feedback
compensatory mechanisms from the ventral tegmental area
provide additional dopamine release presynaptically by using
serotonin 2A (Filip and Cunningham 2002).
The evidence heavily favors the involvement of dopamineserotonin interactions in the mechanism of action of cocaine:
1) Immunohistochemical studies (Steinbusch 1981) and
immunocytochemical studies (Broderick and Phelix 1997).
The latter study shows that ventral tegmental dopamine cell
bodies contain a dense network of serotonin axonal varicosities. 2) Phelix and Broderick (1995) showed extensive overlap
of dopamine and serotonin axons in core and shell, through
neuroanatomic localization of tyrosine hydroxylase- and
serotonin-containing axons in nucleus accumbens. 3) Herve
and colleagues (1987) have shown that serotonin neurons
innervate dopamine neurons synaptically, through light- and
electron microscopy-derived ultra structural evidence. 4) Van
Bockstaele and Pickel (1993), Van Bockstaele and colleagues
(1994), Broderick and Phelix (1997) have produced cellular
evidence for serotonergic excitation of dopamine neurons.
Thus, serotonergic dopamine modulation plays a key role in
shaping the neurochemical proﬁle of cocaine use, and is additionally an efﬁcacious target for atypical antipsychotic therapy.
Indeed, critical evidence from the Broderick research laboratory has recently shown that a biochemically deﬁcient animal,
deﬁcient in dopamine and serotonin in nucleus accumbens, is
unable to react to the administration of the psychostimulant
cocaine (Broderick and Hope 2006).

Cocaine psychosis: a clinical case
MA, a 29-year-old male came into the ER on a Tuesday at
3:00 am, brought by the Emergency Medical Service ambulance,
after calling 911, himself. He complained of hearing voices
telling him to jump in front of the subway. Afraid he might
do it, he called the ambulance. He had been “binging” with
friends “snorting cocaine, and smoking crack” from the previous Friday after work until late Monday evening, missing work
in the process. He felt “paranoid” that evening around 10:00
pm. He was sure, then, he had been followed all day long by
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a Maﬁa gangster intent on killing him. He tried to escape from
the gangster but saw him, through the corner of his eye, hide in
his girlfriend’s apartment building as MA arrived hoping to be
allowed to “crash” in his girlfriend’s apartment. MA rang the
bell, but glancing at him from the inside, the girlfriend did not
open the door. He immediately “understood” she had betrayed
him with the gangster. He went to his parents’ home next but
was turned away. By then he was thoroughly convinced that
there was a wide plot against him. Voices in his head started
commanding him to kill himself. MA roamed the streets where
he got into a “couple” of shouting matches over “nonsense” with
fellow street dwellers. He next went to a friend’s house and tried
to sleep. Again the voices shouted at him insistently and, fearful
he would end up obeying them and killing himself, he called
911. During his ER evaluation, MA had a wild appearance.
He was disheveled and dirty, in a very poor state of hygiene.
Although constitutionally thin, he looked like he had lost some
weight and appeared dehydrated. He looked and behaved in a
suspicious manner and his attitude toward the examiner was
guarded, somewhat hostile, and marginally cooperative. He was
also “scared” and expressed that feeling as pervasive. His affect
was constricted but appropriate to the content of his thinking.
He was alert, fully oriented and his memory was intact. He was
distracted, his speech was rapid, and he was delusional. His insight was poor and his judgment uneven. He was treated in the
ER with intra-muscular combination of haloperidol (a typical
antipsychotic), lorazepam (an anti-anxiety benzodiazepine), and
diphenhydramine (antihistamine with sedative effects). He slept
for many hours, but upon awakening, MA was still psychotic,
which prompted psychiatric hospitalization. On the ward, he was
switched to an atypical antipsychotic.
MA has a long history of cocaine-related incidents including ER visits, brushes with the law, rough-handling of his
girlfriend, and one instance in which he pushed and shoved
his parents, causing injuries that were not life threatening,
but necessitated medical attention. His girlfriend broke up
with him two months later, when she saw his cocaine use was
again escalating after a hiatus; he snorted cocaine occasionally during this hiatus. His parents have closed their doors
to him for the same reason as did his girlfriend. He recently
lost his apartment because he used rent money to feed his
habit. He shuttled for shelter among cocaine-abusing friends’
apartments. Exacerbating this chaos in his life, he is on the
verge of losing his job due to erratic attendance patterns.

Understanding and treating MA
As can be seen in MA’s case, cocaine-induced psychosis
(Brady et al 1991) is the most severe psychiatric consequence
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of abuse. It often courses with persecutory delusions,
auditory, visual, and tactile hallucinations, the latter, of tiny
insects crawling on one’s skin, called formication. Rosse
and colleagues (1994) likened cocaine-induced “paranoia”
to that of schizophrenia. In fact, SPECT studies show that
cocaine-induced changes in blood ﬂow are similar to those
found in schizophrenic persons (Miller et al 1992). Animal
models of cocaine psychosis have long demonstrated that:
1) psychostimulant behavior depends on dopaminergic
nigrostriatal neuronal pathways (Cools and van Rossum
1970; Costall and Naylor 1973; Wise and Bozarth 1987;
Broderick 2002); 2) dopamine antagonists block psychostimulant behavior (Pijnenburg et al 1975).
Psychostimulant-induced neurochemistry and behavior
have become an accepted animal model of certain aspects
of psychoses. This is supported by these ﬁndings: 1) Typical
antipsychotics, known to block mesolimbic and nigrostriatal
dopamine, reduce psychotic symptoms in humans via mesolimbic pathways, but produce movement disorders through
nigrostriatal circuits (Gawin and Kleber 1986; Kleber and
Gawin 1986). 2) Atypical antipsychotic agents, known to act
on mesolimbic/mesocorticolimbic dopaminergic neuronal
pathways (Huff and Adams 1980), reduce both positive and
negative psychotic symptoms in humans (Meltzer 1989).
We have noted earlier that atypicals are quite effective in the management of schizophrenia. In fact, the use
of risperidone also has shown promise in cocaine abusing
schizophrenic persons (Tsuang et al 2002); in controlling
craving for cocaine (Smelson et al 2002); on cocaine-induced euphoria (Newton et al 2001), on cocaine dependence
(Grabowski et al 2000); and on cue-elicited craving for
cocaine (Smelson et al 1997). Broderick and colleagues
(2003) have studied the effects of risperidone on cocaine in
the psychostimulant animal model of psychosis and we have
proceeded further with new neuromolecular imaging (NMI)
research in this area as shown in this paper in Figures 1–3.
NMI, with nationally and internationally patented, miniature
BRODERICK PROBE® sensors and real time electrochemical detection, is cutting-edge research. NMI is conducted
concomitantly and simultaneously with infrared detection
of locomotor (ambulatory) behavioral measurements. This
research has led to the following conclusions: 1) Cocaine
produced withdrawal symptoms in subacute studies, probably
due to neuroadaptive mechanisms, especially in dopamine
and serotonin release in nucleus accumbens. 2) Risperidone
acutely blocked cocaine-enhanced neurochemistry and
behavior, and subacutely improved cocaine’s withdrawal
effects on accumbens neurochemistry. 3) Risperidone thus

Neuropsychiatric Disease and Treatment 2007:3(4)

Novel risperidone research for schizophrenic and cocaine psychosis

Neurochemical concentration (%
baseline)

500

5-HT

400

DA

300

200

100

0
–30 –20 –10 0

10 20 30 40 50 60 70 80 90 100 110 120
Time (min)

Baseline

Post-Cocaine (10mg/kg i.p.)

Figure 1A Day 1 The effect of cocaine (10 mg/kg i.p.) on adult, male Sprague-Dawley laboratory rats (n = 4). Studies were done with neuromolecular imaging (NMI) based on
in vivo electrochemistry. The imaging was performed with the BRODERICK PROBE® sensors. Sensors were implanted in NAcc and verified by the blue dot perfusion method.
DA and 5-HT were detected selectively in the freely moving animal (concurrent behavioral data are presented below). Cocaine increased DA release in NAcc up to 75% over
baseline (unpaired t-test, p < 0.0001 compared with preadministration), and increased 5-HT by 190% over baseline (unpaired t-test p < 0.0001 compared with baseline).

500

Neurochemical concentration (%
baseline)

5-HT
400

DA

300

200

100

0
–30 –20 –10

0

10

20

30

40

50

60

70

80

90

Time (min)
Figure 1B Day 2 Withdrawal effects after a single injection of cocaine (10 mg/kg i.p.) in adult, male Sprague-Dawley laboratory rats (n = 4) measured one day after prior
administration. Studies were performed with the same paradigm as described in Figure 1A. Withdrawal effects were as follows: DA was significantly decreased from baseline
(unpaired t-test p < 0.0001) and 5-HT was higher than at baseline only at the first point likely due to “novelty chamber effects” (unpaired t-test p < 0.05). Moreover, both
DA and 5-HT were significantly lower than their Day-1 post-cocaine administration levels (unpaired t-test p < 0.0001).
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Figure 2A Day 1 The effect of co-administration of risperidone (2mg/kg s.c.) and cocaine (10 mg/kg i.p.) on adult, male Sprague-Dawley laboratory rats (n = 4). 5-HT
release in NAcc after administration of risperidone and cocaine combination, did not significantly differ from baseline values (p = 0.415, unpaired t-test). As evidenced by
Naiker, et al, 2mg/kg risperidone in the male laboratory rat is equivalent to a low-dose of single risperidone treatment in human psychotic patients. Furthermore, 5-HT
release was found to be significantly lower when risperidone was administered with cocaine compared with cocaine alone (unpaired t-test, p < 0.0001). DA release was
significantly different from its baseline upon co-administration (unpaired t-test, p < 0.05). Importantly, effects of risperidone and cocaine on DA release in NAcc was significantly decreased (p < 0.0001) from cocaine effects on DA release when cocaine was given alone.
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Figure 2B Day 2 Effects after a single co-administration of risperidone (2 mg/kg s.c.) and cocaine (10 mg/kg i.p.) to adult, male Sprague-Dawley laboratory rats (n = 3).
Absence of typical withdrawal effects is evident relative to cocaine, as follows: risperidone-cocaine did not differ significantly from baseline on the second day (unpaired
t-test, p = 0.3285 for 5-HT and p = 0.4433 for DA). Additionally, there was no significant difference between risperidone-cocaine on the first day and on the second day (p
= 0.2994 for 5-HT and p = 0.0514 for DA). Thus, the data suggest that risperidone may be effective in the treatment of cocaine psychosis both for its impact on negative
symptoms and its alleviation of acute withdrawal effects from cocaine.
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Figure 3A Day 1 The effect of cocaine (10 mg/kg i.p.) on adult male Sprague
Dawley laboratory rats with respect to peripheral ambulations and the effect of
co-administration of risperidone (2 mg/kg s.c.) and cocaine (10 mg/kg i.p.) are
depicted. The effect of cocaine alone on ambulations post-administration was
significant compared to baseline values (unpaired t-test p < 0.01). In combination
with the atypical antipsychotic risperidone, ambulations are no longer significantly
greater than their baseline values (unpaired t-test p = 0.1837). Therefore, risperidone has been demonstrated to block the behavioral ambulatory effects of cocaine.
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Figure 3B Day 2 Adult male Sprague-Dawley laboratory rats who received
cocaine (10 mg/kg i.p.) and co-administered risperidone (2 mg/kg s.c.) and cocaine
(10 mg/kg i.p.) were monitored one day after drug administration to detect
possible withdrawal effects with respect to ambulations. Neither cocaine nor
risperidone showed significant second-day effects over baseline (unpaired t-test,
p = 0.2478 and p = 0.3605, respectively).
Note: First point in both groups denotes “novelty to chamber” effects.

may be a viable psychopharmacological tool in the treatment
of cocaine addiction, withdrawal, and psychosis.

Closing comments on clinical
management of schizophrenia
and cocaine abuse
We have shown that this novel research points toward the usefulness of atypical antipsychotic agents in the treatment of schizophrenia and cocaine-related disorders. While the usefulness of
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atypical antipsychotic agents is well established in the treatment
of schizophrenia, the potential usefulness of these agents remains
very good in the treatment of cocaine-related disorders.
Again, because schizophrenia and cocaine abuse are
multifaceted conditions, no simple solution exists for their
clinical management. While reliance on established treatment
guidelines and best practices is the optimal modus operandi,
clinicians must assess patient presentation to institute the
proper individually-tailored management strategy. We strongly
advocate that clinicians add to their management strategies
the most direct conclusions of research, such as that reported
herein, whose mechanisms and hypotheses are sound. These
novel translated research ﬁndings can add an important dimension to clinical protocol-building and provide up-to-the-minute
potential solutions to difﬁcult problems.
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